Collegeville, PA, United States of America

Laura M Seestaller-Wehr

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Laura M Seestaller-Wehr: Innovator in Multiple Myeloma Prognosis

Introduction

Laura M Seestaller-Wehr is a notable inventor based in Collegeville, PA (US). She has made significant contributions to the field of medical research, particularly in the prognosis and treatment of multiple myeloma. Her innovative work has led to the development of methods that enhance patient care and treatment outcomes.

Latest Patents

Laura holds a patent for a prognostic method that determines the prognosis of multiple myeloma in patients by measuring the expression of BCMA in a sample. This patent also includes methods for treating multiple myeloma by administering an effective amount of an antigen-binding protein that binds BCMA. Additionally, she has developed kits for measuring BCMA expression in samples, which are crucial for effective diagnosis and treatment.

Career Highlights

Laura is currently associated with GlaxoSmithKline Intellectual Property Development Limited, where she continues to advance her research and innovations. Her work is instrumental in bridging the gap between scientific research and practical applications in the medical field.

Collaborations

Laura has collaborated with esteemed colleagues, including Danton Bounds and Jenny L Craigen, to further her research initiatives. These collaborations have enriched her work and contributed to the development of effective treatment methodologies.

Conclusion

Laura M Seestaller-Wehr is a pioneering inventor whose work in multiple myeloma prognosis and treatment is making a significant impact in the medical community. Her innovative methods and dedication to research exemplify the importance of advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…